Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;13(4):e069195.
doi: 10.1136/bmjopen-2022-069195.

Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment

Yilin Chen  1 , Enrique M Saldarriaga  2 , Michalina A Montano  3   4 , Kenneth Ngure  5 , Nicholas Thuo  6 , Catherine Kiptinness  6 , Maeve Rafferty  7 , Fern Terris-Prestholt  8 , Andy Stergachis  2   4 , Melissa Latigo Mugambi  4 , Katrina F Ortblad  9 , Monisha Sharma  4
Affiliations

Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment

Yilin Chen et al. BMJ Open. .

Abstract

Introduction: Pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV acquisition, but coverage remains low in high prevalence settings. Initiating and continuing PrEP via online pharmacies is a promising strategy to expand PrEP uptake but little is known about user preferences for this strategy. We describe methods for a discrete choice experiment (DCE) to assess preferences for PrEP delivery from an online pharmacy.

Methods and analysis: This cross-sectional study is conducted in Nairobi, Kenya, in partnership with MYDAWA, a private online pharmacy retailer with a planned sample size of >400 participants. Eligibility criteria are: ≥18 years, not known HIV-positive and interested in PrEP. Initial DCE attributes and levels were developed via literature review and stakeholder meetings. We conducted cognitive interviews to assess participant understanding of the DCE survey and refined the design. The final DCE used a D-efficient design and contained four attributes: PrEP eligibility assessment, HIV test type, clinical consultation type and user support options. Participants are presented with eight scenarios consisting of two hypothetical PrEP delivery services. The survey was piloted among 20 participants before being advertised on the MYDAWA website on pages displaying products indicating HIV risk (eg, HIV self-test kits). Interested participants call a study number and those screened eligible meet a research assistant in a convenient location to complete the survey. The DCE will be analysed using a conditional logit model to assess average preferences and mixed logit and latent class models to evaluate preference heterogeneity among subgroups.

Ethics and dissemination: This study was approved by the University of Washington Human Research Ethics Committee (STUDY00014011), the Kenya Medical Research Institute, Nairobi County (EOP/NMS/HS/128) and the Scientific and Ethics Review Unit in Kenya (KEMRI/RES/7/3/1). Participation in the DCE is voluntary and subject to completion of an electronic informed consent. Findings will be shared at international conferences and peer-reviewed publications, and via engagement meetings with stakeholders.

Keywords: HEALTH SERVICES ADMINISTRATION & MANAGEMENT; HIV & AIDS; Health economics; International health services; Public health; Telemedicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study design flowchart. DCE, discrete choice experiment; ePrEP, online PrEP; PrEP, pre-exposure prophylaxis.
Figure 2
Figure 2
Example of DCE choice task. DCE, discrete choice experiment; PrEP, pre-exposure prophylaxis; SMS, short messaging service.
See this image and copyright information in PMC

References

    1. Cherutich P, Kaiser R, Galbraith J, et al. . Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS One 2012;7:e36797. 10.1371/journal.pone.0036797 - DOI - PMC - PubMed
    1. CDC . Kenya country profile: centers for disease control and prevention. 2022. Available: https://www.cdc.gov/globalhivtb/where-we-work/kenya/kenya.html [Accessed 04 Aug 2022].
    1. Ortblad KF, Baeten JM, Cherutich P, et al. . The Arc of HIV epidemics in sub-Saharan Africa: new challenges with concentrating epidemics in the era of 90-90-90. Curr Opin HIV AIDS 2019;14:354–65. 10.1097/COH.0000000000000569 - DOI - PMC - PubMed
    1. The national AIDS control council. 2022. Available: https://nacc.or.ke/ [Accessed 17 Jul 2022].
    1. Kenya Ministry of Health . Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection in kenya - 2018 edition. Nairobi, 2018.

Publication types

MeSH terms

Substances